GlassScriptPhysician profile
Andrew Donald Mowery
NPI 1104084896
$8,938.16
in general payments reported to CMS, 2019-2025
38 companies · $1,944 in 2025
The $1,944 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $777 · 2020: $165 · 2021: $681 · 2022: $1,341 · 2023: $1,656 · 2024: $2,374 · 2025: $1,944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,963 · Education: $10.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,962.96 |
| Education | $10.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,963.08 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,352.41 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $1,220.31 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $615.16 | 2019-2025 | |
| Celgene Corporation | $501.72 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $410.19 | 2019-2025 | Tremfya, Stelara, Remicade |
| Gilead Sciences, INC. | $387.18 | 2019-2025 | |
| Genzyme Corporation | $302.72 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $194.46 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $183.82 | 2023-2025 | Omvoh, Zepbound |
| Ironwood Pharmaceuticals, INC | $179.11 | 2021-2024 | Linzess |
| Ipsen Biopharmaceuticals, INC | $166.68 | 2024-2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $159.42 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $152.39 | 2019-2025 | Ocaliva |
| Fresenius Kabi USA, LLC | $145.25 | 2023-2025 | Idacio, Adalimumab-Aacf |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $128.05 | 2023-2025 | Ibsrela |
| Boston Scientific Corporation | $127.67 | 2022 | |
| Merck Sharp & Dohme LLC | $117.91 | 2019-2023 | Dificid, Zinplava |
| Daiichi Sankyo INC. | $102.91 | 2019-2024 | Injectafer |
| Aimmune Therapeutics, INC. | $71.84 | 2023-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $60.30 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $49.95 | 2025 | Wegovy |
| Romark Laboratories, Lc | $32.81 | 2019-2020 | |
| Amgen INC. | $32.23 | 2022 | |
| Madrigal Pharmaceuticals | $31.96 | 2025 | Rezdiffra |
| Qol Medical, LLC | $30.26 | 2019 | |
| Braintree Laboratories, INC. | $28.85 | 2020-2025 | Suflave |
| Allergan, INC. | $24.70 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.40 | 2023 | Cyltezo |
| Ferring Pharmaceuticals INC. | $20.15 | 2023 | Rebyota |
| Celltrion USA INC. | $18.70 | 2024 | Vegzelma |
| Alnylam Pharmaceuticals INC. | $17.33 | 2024 | Givlaari |
| Exact Sciences Corporation | $16.62 | 2024 | Cologuard Collection Kit |
| Shire North American Group INC | $16.22 | 2019 | |
| Albireo Pharma, INC. | $15.89 | 2023 | Bylvay |
| Axonics, INC. | $14.05 | 2024 | Axonics |
| Medtronic, INC. | $13.98 | 2022 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Mowery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.